Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CS-12192 by Shenzhen Chipscreen Biosciences for Graft Versus Host Disease (GVHD): Likelihood of Approval
CS-12192 is under clinical development by Shenzhen Chipscreen Biosciences and currently in Phase I for Graft Versus Host Disease (GVHD)....